Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets open in the red
Tue, 8 Jul 09:30 am

The major Asian stock markets have opened in the red with stock markets in Singapore (down 0.3%) and South Korea (down 0.2%) leading the losses. However, the stock markets in Indonesia (up 0.9%) and Taiwan (up 0.1%) have opened on a positive note.

The Modi Government is all set present its first Rail Budget today. A hike in the FDI limit for railways, greater private sector participation and investments for infrastructure upgradation will be the are some of the key areas likely to be in focus.

The Indian share markets have opened the day in the red. The sectoral indices have opened mixed with the stocks in realty and metal space leading the losses. However, stocks in the software and consumer durables space were leading the gains.

The Sensex today is down by around 37 points (0.1%), while the NSE-Nifty is down by around 14 points (0.2%). The midcap and smallcap stocks have also opened in the red with BSE Mid Cap and BSE Small Cap indices down by around 0.2%nd 0.3% respectively. The rupee is currently trading at Rs 59.94 to the US dollar.

Indian Pharma stocks have opened the day on a mixed note with Natco Pharma Ltd and Sun Pharma Ltd leading the gains. However, Orchid Chemicals Ltd and Dishman Pharma Ltd were facing maximum selling pressure. As per a leading financial daily, Cipla Ltd is likely to invest around Rs 10.3 bn in UK over next few years for launch and development of new drugs in line with its global footprint expansion plans. The range of drugs will include the areas of respiratory, oncology and antiretroviral segments. The investment will include research and development, clinical trials and further expansion internationally and in the UK. The company will offer high quality affordable medicines to British National Health Service (NHS).

Mining stocks have opened the day mainly in the red with Ashapura Minechem Ltd and Sesa Sterlite Ltd leading the losses. As per a leading financial daily, Coal India Ltd (CIL) plans to take up 118 projects that are likely to produce 354 million tonnes per annum (MTPA) output in three years. The estimated contribution, as stated by the Minister of State for Coal, Power, New and Renewable Energy Piyush Goyal in 2016-2017 is around 137.77 MT. These projects would be taken by seven subsidiaries of CIL. Besides, the Mr Goyal has stated that Singareni Collieries Company Limited (SCCL) will also take up nine projects for an ultimate capacity of 13 MTPA during the 12th plan and the envisaged contribution from the same in 2016-17 is 4.04 MT.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open in the red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.